Pluristem Therapeutics Inc (PSTI)

[FDApproved]

Nir: The trial results showed success. What do you think about them?

Zami Aberman: I was happy that PLX-R18 cells showed success in NHPs, as many companies fail to successfully replicate trial success from smaller animals to NHPs. The results we received are important in order to carry out our next steps and support the pivotal trial. Soon we’ll publish more data that will shed more light on the advantages of our treatment.

Nir: From personal experience with a member of my family, cancer treatment with radiation is a very difficult process that may affects the patient’s hematology and immune system. Can Pluristem’s PLX-R18 cells be used for supporting cancer treatment?

Zami Aberman: At the moment, the FDA and the Israeli Ministry of Health approved an initial trial to verify the safety profile for the treatment of bone marrow failure. If successful, we can start fulfilling those requests for supportive treatment.

Nir: Are there any trials about supporting cancer treatment in Fukushima?

Zami Aberman: In Fukushima, there are ongoing studies for the treatment of other component of ARS such as GI, Lung and Skin. We are currently focused on receiving approval for treating H-ARS. Our trials indicate that our cells may be able to help the blood system recover in cases such as patients who have undergone chemotherapy treatment or suffer from genetic dieses such as aplastic anemia.

Nir: Does Pluristem intend to pursue the indication of cancer support treatment?

Zami Aberman: We’re actually waiting for the completion of the ARS trials and approval of that treatment. FDA approval will mean the cells are safe and efficient for treating radiation damages, and might be eligible for “off label” use

https://seekingalpha.com/instablog/4519051-nir-etkovitz/5011590-pluristem-successful-ars-trial-opens-door-cancer-support-treatment-interview-co-ceo-chairman